Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: A phase II trial of the NSABP foundation research group

Clinical Breast Cancer

Volumn 8, Issue 3, 2008, Pages 257-263

  Hamm, John T ^a,b   Wilson, John W ^a,c   Rastogi, Priya ^a,d,e   Lembersky, Barry C ^a,e   Tseng, George C ^a,c   Song, Young K ^a   Kim, Wanseop ^a   Robidoux, André ^a,f   Raymond, Jane M ^a,g   Kardinal, Carl G ^a,h   Shalaby, Ibrahim A ^a,i   Ansari, Rafat ^a,j   Paik, Soonmyung ^a   Geyer, Charles E ^a,g   Wolmark, Norman ^a,g  

^a NSABP Foundation Inc   (United States)

^b Norton Healthcare   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f Centre Hospitalier   (Canada)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

^h Alton Ochsner   (United States)

ⁱ Joe Arrington Cancer Center   (United States)

^j Northern Indiana Cancer Research Consortium   (United States)

more..

Author keywords

Desquamation; Diagonal linear discriminant analysis; Gene expression profiling; Myalgia; P reoperative chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIRUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALOSIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EMBOLISM; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE EXPRESSION PROFILING; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOXIA; INFECTION; LUNG FIBROSIS; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RASH; RNA PROBE; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR CELL; URTICARIA; VOMITING;

EID: 46949086552     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.029     Document Type: Article

References (31)

1. Schick P, Goodstein J, Moor J, et al. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983; 22:278-82.
2. Sorace RA, Bagley CS, Lichter AS, et al. The management of non-metastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation with or without debulking surgery. World J Surg 1985; 9:775-85.
3. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82:1539-45.
4. Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983; 51:763-8.
5. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage HI primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:2507-16.
6. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990; 66:1387-91.
7. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991; 2:347-54.
8. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-9.
9. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16:93-100.
10. Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994; 74:1283-8.
11. DeLena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981; 4:229-36.
12. Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988; 6:261-9.
13. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-93.
14. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemo-therapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
15. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
16. Bear HD, Anderson S, Brown A, et al. The effect of tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21:4165-74.
17. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24:2019-27.
18. Conte PF, Gennari A, Donati S, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 2001; 68:171-9.
19. Therasse E Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
20. Armitage P, Berry G, Matthews JNS, eds. Statistical Methods in Medical Research. Maiden, MA: Blackwell Science; 2002.
21. Cappuzzo F, Mazzoni, F, Gennari A, et al. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 2004; 90:31-5.
22. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005; 23:1401-8.
23. Conte PF, Donati S, Gennari A, et al. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. Br J Cancer 2005; 93:406-11.
24. Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24:1839-45.
25. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23:7265-77.
26. Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008; 26:246-52.
27. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12:1294-300.
28. Colomer R, Llombart A, Lluch A, et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000; 27:20-4.
29. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-9.
30. Ferriere JE Assier I, Cure H, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21:117-20.
31. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4:125-31.